Keyword: Ziarco


3. Novartis

Novartis has in recent years remained a big hitter in the R&D stakes, and it continues its run with an impressive $9 billion spent on R&D last year—although that was only slightly up on the $8.93 billion it had spent the year before.

Novartis boosts dermatology pipeline with Ziarco buy

In the week that Pfizer was rewarded for its $4.5 billion buyout of Anacor after the FDA approved its eczema med Eucrisa (crisaborole), rival Big Pharma Novartis wants to get in on the act as it announces a deal to buy Ziarco and its leading eczema candidate.